Showing results (221-230 of 350) with videos related to
Sort By:
Pageof 35
Archives of Dermatological Research|April 29, 2025
Systemic Janus kinase inhibitors in the management of granuloma annulareScott Stratman, Shivkar Amara, Kathryn Jayne Tan, et al.Journal of the American Academy of Dermatology|August 20, 2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registryAlexis Ogdie, Ryan W Harrison, Robert R McLean, et al.Dermatology and Therapy|February 23, 2022
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisAndrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, et al.Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.Dermatology and Therapy|October 27, 2021
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.Pageof 35